SequelSEC

Lyell Immunopharma, Inc. LYEL

Pharmaceutical Preparations · CIK 0001806952 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$36.00K
Fiscal year ended 2025-12-31
Operating income
-$269.40M
Fiscal year ended 2025-12-31
Free cash flow
-$150.80M
Fiscal year ended 2025-12-31

Lyell Immunopharma, Inc. (LYEL) reported revenue of $36.00K and net income of -$274.45M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Lyell Immunopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Lyell Immunopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$36.00K$61.00K$130.00K$84.68M$10.65M$7.76M$657.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$269.40M-$358.76M-$247.01M-$187.06M-$214.78M-$211.94M-$102.09M
Net income-$274.45M-$342.99M-$234.63M-$183.12M-$250.22M-$204.47M-$129.38M
Research & developmentUnavailableUnavailable$182.94M$159.19M$138.69M$182.24M$63.60M
Weighted-average diluted sharesshares 17.09Mshares 13.07Mshares 12.55Mshares 247.08Mshares 135.92Mshares 13.26MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-16.06$-26.23$-18.70$-0.74$-1.84$-15.69$-24.04
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$45.14M$52.04M$66.98M$117.31M$89.06M$46.88M$39.15M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Lyell Immunopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$60.18M$105.60M$145.65M$123.55M$293.83M$140.41M$96.67M
Total assets$340.05M$490.86M$750.03M$937.56M$1.13B$908.28MUnavailable
Current assets$260.94M$379.59M$554.69M$651.30M$626.29M$617.55MUnavailable
Total liabilities$91.85M$108.04M$95.08M$104.31M$197.62M$189.84MUnavailable
Current liabilities$49.41M$53.79M$34.52M$37.03M$46.74M$49.28MUnavailable
Total equity incl. NCI$248.20M$382.82M$654.95M$833.25M$929.79M-$292.53M-$111.11M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$1.01B$519.16M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.89M$5.37M$4.82M$3.92M$3.21M$9.40MUnavailable

Cash flow

Lyell Immunopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$150.02M-$162.39M-$163.69M-$169.56M-$126.25M-$160.87M$39.47M
Capital expenditures$780.00K$464.00K$2.69M$24.28M$65.50M$51.48M$16.05M
Investing cash flow$54.10M$122.42M$184.05M-$11.54M-$121.57M-$273.52M-$422.43M
Financing cash flow$50.41M$1.33M$1.74M$10.64M$401.24M$476.79M$351.16M
Net change in cash-$45.52M-$38.64M$22.10M-$170.46M$153.42M$42.40M-$31.80M
Stock-based compensation$41.83M$33.14M$47.08M$81.92M$62.20M$33.26M$15.73M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable$0$0$11.81M$185.00K
Depreciation & amortization$11.54M$19.63M$20.25M$18.02M$13.62M$4.29M$1.26M

Derived

Lyell Immunopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$150.80M-$162.86M-$166.38M-$193.83M-$191.75M-$212.36M$23.43M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-748344.4%-588123.0%-190006.2%-220.9%-2016.7%-2732.6%-15538.7%
FCF margin-418900.0%-266980.3%-127984.6%-228.9%-1800.5%-2737.9%3565.8%
SBC / revenue116191.7%54334.4%36218.5%96.7%584.0%428.8%2394.5%
Current ratio5.28x7.06x16.07x17.59x13.40x12.53xUnavailable
Revenue YoY growth-41.0%-53.1%-99.8%695.1%37.3%1080.5%Unavailable
Net margin-762355.6%-562285.2%-180486.2%-216.2%-2349.5%-2636.3%-19692.1%
R&D / revenueUnavailableUnavailableUnavailableUnavailable1302.3%2349.7%9679.6%
CapEx / revenue2166.7%760.7%2066.2%28.7%615.1%663.8%2442.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LYEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.